What is Chardan Capital's Forecast for PRAX FY2025 Earnings?

Key Points

• Chardan Capital has reduced its FY2025 earnings estimate for Praxis Precision Medicines to ($12.80) per share, down from ($11.25), while maintaining a "Buy" rating and a target price of $80.00.
• Despite lower earnings estimates, the stock has received multiple "Buy" ratings from different brokerages, with price targets ranging from $80.00 to $115.00.
• Praxis Precision Medicines reported a quarterly earnings loss of ($3.31) per share, slightly beating the consensus estimate of ($3.40).

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Equities research analysts at Chardan Capital decreased their FY2025 earnings per share estimates for shares of Praxis Precision Medicines in a research report issued to clients and investors on Wednesday, August 6th. Chardan Capital analyst R. Li now forecasts that the company will earn ($12.80) per share for the year, down from their prior estimate of ($11.25). Chardan Capital has a "Buy" rating and a $80.00 price objective on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($10.22) per share. Chardan Capital also issued estimates for Praxis Precision Medicines' FY2026 earnings at ($5.90) EPS.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($3.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.40) by $0.09. Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 60.07%.

PRAX has been the subject of several other reports. HC Wainwright restated a "buy" rating and set a $115.00 price objective (up from $105.00) on shares of Praxis Precision Medicines in a research report on Tuesday, August 5th. Needham & Company LLC restated a "buy" rating and set a $80.00 price objective on shares of Praxis Precision Medicines in a research report on Thursday, June 12th. Wedbush raised their price objective on shares of Praxis Precision Medicines from $26.00 to $28.00 and gave the stock an "underperform" rating in a research report on Monday, May 5th. Finally, Oppenheimer raised their price objective on shares of Praxis Precision Medicines from $97.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $95.22.

Praxis Precision Medicines Trading Down 1.6%

PRAX stock traded down $0.77 during mid-day trading on Monday, hitting $48.28. 107,363 shares of the company were exchanged, compared to its average volume of 453,630. The business has a 50 day simple moving average of $48.51 and a 200-day simple moving average of $47.64. The stock has a market capitalization of $1.02 billion, a PE ratio of -3.93 and a beta of 2.62. Praxis Precision Medicines has a 1-year low of $26.70 and a 1-year high of $91.83.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of Praxis Precision Medicines by 24.0% during the fourth quarter. JPMorgan Chase & Co. now owns 9,693 shares of the company's stock worth $746,000 after buying an additional 1,879 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Praxis Precision Medicines by 335.8% during the fourth quarter. Alliancebernstein L.P. now owns 78,627 shares of the company's stock worth $6,051,000 after buying an additional 60,587 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Praxis Precision Medicines by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 406,711 shares of the company's stock worth $31,308,000 after buying an additional 7,873 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Praxis Precision Medicines by 46.8% during the fourth quarter. Wells Fargo & Company MN now owns 8,612 shares of the company's stock worth $663,000 after buying an additional 2,746 shares during the last quarter. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Praxis Precision Medicines during the fourth quarter worth $231,000. 67.84% of the stock is currently owned by institutional investors and hedge funds.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.